Clinical trials: NSCLC, Squamous or Non-Squamous
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous…
- Trial name
- NCT00700180
- Testing
- bevacizumab [Avastin], Carboplatin-based chemotherapy
- Where
- 59 sites in Australia, Belgium and 14 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054392
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 57 sites in United States
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-Small-Cell Lung
GIOTRIF rPMS in Korean Patients With NSCLC
To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Trial name
- NCT02285361
- Testing
- GIOTRIF 20mg, GIOTRIF 40mg, GIOTRIF 30mg
- Where
- South Korea
- Volunteers
- 1,272 people
- Sponsor
- Boehringer Ingelheim
Lung Non-Squamous Non-Small Cell Carcinoma
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable).
- Trial name
- NCT07229339
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 42 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
This 4 arm study in patients with advanced Stage IIIb/IV non-small cell cancer (NSCLC) who failed at least one standard chemotherapy regimen will determine the proportion of patients with progression-free survival at 12 weeks…
- Trial name
- NCT00760929
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with…
- Conditions
- Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
- Trial name
- NCT05651022
- Testing
- Decoy20, Tislelizumab
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indaptus Therapeutics, Inc
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）
This is a multicenter, open-Lable, randomized, phase III clinical study to compare the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous) (JS001sc) and Toripalimab injection (JS001) in…
- Trial name
- NCT06505837
- Testing
- JS001sc (360mg Subcutaneous injection) and pemetrexed/platinum-containing chemotherapy, JS001 (240mg intravenous infusion) and pemetrexed/platinum-containing chemotherapy
- Where
- China
- Volunteers
- 395 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.
- Trial name
- NCT03810872
- Testing
- Afatinib, Paclitaxel
- Where
- 5 sites in Belgium
- Volunteers
- 87 people
- Sponsor
- Universitair Ziekenhuis Brussel
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006004
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 16 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumor, Adult, Triple Negative Breast Cancer
AVID100 in Advanced Epithelial Carcinomas
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT03094169
- Testing
- AVID100 IV
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Formation Biologics
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
Lung Cancer
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tumor tissue, blood, and urine in the laboratory from patients receiving erlotinib may help doctors predict how patients will respond to treatment.
- Trial name
- NCT00550537
- Testing
- bevacizumab, carboplatin, erlotinib hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 116 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer
- Trial name
- NCT04432207
- Testing
- IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3
- Where
- 6 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Imugene Limited
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III…
- Trial name
- NCT07122687
- Testing
- Pemetrexed, Cisplatin, IBI363
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC)
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety…
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
- Trial name
- LB-LR1109 (NCT06332755)
- Testing
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- LG Chem